https://finance.yahoo.com/news/cstone-announces-nmpa-approval-sugemalimab-041000120.html
Late Stage Cancer
November 8, 2023
Domvanalimab Regimen Shows Potential in First-Line GI Cancer Treatment
https://www.targetedonc.com/view/domvanalimab-regimen-shows-potential-in-first-line-gi-cancer-treatment
September 28, 2023
Opdivo and Stivarga Plus Chemotherapy Improves Outcomes in Certain Gastric Cancers
https://www.curetoday.com/view/opdivo-and-stivarga-plus-chemotherapy-improves-outcomes-in-certain-gastric-cancers
August 28, 2023
Zhen Explores the Role of Immunotherapy in Upper GI Cancers
https://www.targetedonc.com/view/zhen-explores-the-role-of-immunotherapy-in-upper-gi-cancers
August 24, 2023
Advanced Esophageal Cancer and Immunotherapy
https://www.verywellhealth.com/esophageal-cancer-immunotherapy-7644000
June 27, 2023
Pembrolizumab/Chemo Improves Responses But Not EFS in Gastric/GEJ Cancer
https://www.cancernetwork.com/view/pembrolizumab-chemo-improves-responses-but-not-efs-in-gastric-gej-cancer
May 13, 2023
Tislelizumab Plus Chemotherapy Improves Overal Survival in ESCC
https://www.targetedonc.com/view/tislelizumab-plus-chemotherapy-improves-overal-survival-in-escc
April 21, 2023
BeiGene-Novartis gastric cancer drug succeeds in late-stage trial
https://www.reuters.com/business/healthcare-pharmaceuticals/beigenes-gastric-cancer-drug-meets-main-goal-late-stage-trial-2023-04-20/
February 11, 2023
Claudin 18.2 Represents New Druggable Target for CLDN18.2+/HER2-, Advanced/Metastatic Gastric and GEJ Adenocarcinoma
https://www.targetedonc.com/view/claudin-18-2-represents-new-druggable-target-for-cldn18-2-her2–advanced-metastatic-gastric-and-gej-adenocarcinoma
December 16, 2022
Astellas Announces Zolbetuximab Meets Primary Endpoint in Phase 3 GLOW Trial as First-Line Treatment in Claudin 18.2 Positive, HER2-negative Locally Advanced Unresectable or Metastatic Gastric and Gastroesophageal Junction (GEJ) Cancers
https://www.prnewswire.com/news-releases/astellas-announces-zolbetuximab-meets-primary-endpoint-in-phase-3-glow-trial-as-first-line-treatment-in-claudin-18-2-positive-her2-negative-locally-advanced-unresectable-or-metastatic-gastric-and-gastroesophageal-junction-gej-c-301704713.html